High CV risk in young people is a 'delayed' crisis

Published Date: 08 Mar 2023

Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.

Read Full News

Latest News

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

RLS-1496 Cream Reduces Actinic Keratosis Lesions Mary Spellman, MD

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Why Dermatologists Should Stay Involved in Advanced Cutaneous SCC Shannon C. Trotter, DO

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

Todays Updates

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Todays Updates

Episode 178: Evolving Approaches to Epilepsy Clinical Trial Design Isabella Ciccone, MPH, M. Scott Perry, MD, Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials Isabella Ciccone, MPH

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Latest News

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Shannon C. Trotter, DO, FAOCD, discusses immunotherapy in advanced cutaneous squamous cell carcinoma and why dermatologists should stay involved.

News All Time

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Recommended News For You

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

AI tool automates liver tumor detection and monitoring

AI could help improve early detection of interval breast cancers

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer

Why Are These Bones and Teeth Where They Shouldn't Be?

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

Recommended Articles For You

Liquid Biopsies in Hematology: A Window into the Disease 

Immune Niches Supporting Tumor Resistance: Mechanisms, Clinical Implications, and Emerging Therapies 

Bone Marrow Regenerative Capacity and Hematologic Recovery 

Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'

2.

Renewing the call for a national Cancer Patient's Bill of Rights

3.

Woman Loses 6-Year Battle With Mouth Tumor

4.

Pressing the Sleep button could have a positive impact on cognition.

5.

FDA Approves Iberdomide Combo for Multiple Myeloma

1.

Breaking Barriers: Innovative Approaches in Brain Tumor Treatment

2.

HPV and Immunotherapy in Cancer Survivorship: National Cancer Survivors Day Review

3.

Polycythemia Vera: A Historical Perspective and Contemporary Management

4.

ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring

5.

Prevention Through Survivorship-Focused Strategies for Preserving Functional Independence After Cancer

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

2.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

3.

The Role of Platelets in Normal Blood Clotting

4.

Comprehensive Update on Hematology

5.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot